Drug Profile
Research programme: ethylenediamine antibiotics - Sequella
Latest Information Update: 29 Jan 2018
Price :
$50
*
At a glance
- Originator Sequella
- Class Ethylenediamines
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 29 Jan 2018 Discontinued for Clostridium difficile infections in USA (unspecified route) (Sequella pipeline, January 2018)
- 16 Jul 2016 No recent reports of development identified for research development in Clostridium-infections in USA
- 05 Apr 2011 Early research in Clostridium infections in USA (unspecified route)